Additional Relevant Details Otonomy, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first patients in a Phase 2 clinical trial evaluating a single administration of OTIPRIO (ciprofloxacin otic suspension) for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). Otonomy previously completed a Phase 2 trial that successfully demonstrated the feasibility of administering OTIPRIO to pediatric patients with AOMT in an office setting. This second Phase 2 trial is designed to determine the most appropriate OTIPRIO dose for further development in this indication.